Neoleukin Therapeutics, Inc. Sustainability Profile
Neoleukin Therapeutics, Inc., a pioneering biotechnology firm based in the United States, focuses on the development of innovative immunotherapies for cancer and autoimmune diseases. Founded in 2018, the company has rapidly advanced its proprietary Neoleukin platform, which leverages computational design to create novel protein therapeutics. Headquartered in Seattle, Washington, Neoleukin operates primarily within the biopharmaceutical industry, aiming to revolutionise treatment options through its unique approach to protein engineering. The company’s lead product candidates, designed to mimic the activity of naturally occurring cytokines, stand out for their potential to enhance immune responses while minimising side effects. With a commitment to scientific excellence, Neoleukin Therapeutics has positioned itself as a notable player in the immunotherapy landscape, attracting significant attention for its innovative solutions and promising clinical developments.
DitchCarbon Score
How does Neoleukin Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neoleukin Therapeutics, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neoleukin Therapeutics, Inc.'s reported carbon emissions
Neoleukin Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a merged entity, Neoleukin's climate commitments and emissions data may be influenced by its corporate family relationships; however, no specific data or initiatives have been inherited from parent organisations. The lack of reported emissions and reduction initiatives suggests that Neoleukin Therapeutics, Inc. is still in the early stages of developing its climate strategy and commitments. In the broader context of the biotechnology industry, companies are increasingly focusing on sustainability and carbon reduction, which may prompt Neoleukin to establish its own targets and initiatives in the future.
How Carbon Intensive is Neoleukin Therapeutics, Inc.'s Industry?
How Carbon Intensive is Neoleukin Therapeutics, Inc.'s Location?
Neoleukin Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Neoleukin Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
